百时美施贵宝Bristol Myers Squibb Co. (BMY) 2020年年度报告「NYSE」.pdf

1、2020 Annual ReportOur MissionTo discover,develop and deliver innovative medicines that help patients prevail over serious diseasesOur VisionTo be the worlds leading biopharma company that transforms patients lives through scienceOur ValuesIntegrity|Innovation|Urgency|Passion|Accountability|Inclusion

2、Cover image:During a year when most of us were separated by the pandemic,our global collective efforts ensured that individual contributions came together to make a significant impact for patients.2020 Full-Year RevenuesGAAP Full-Year Change vs.Prior Year*63%Worldwide Revenues$42.5BPro Forma Full-Ye

3、ar Change vs.Prior Year*7%“We created a leading biopharma company that combines the agility of a biotech company with the reach and resources of an established pharmaceutical corporation.”We worked hard to deliver on our mission by maintaining an uninterrupted supply of medicines to patients,launchi

4、ng new products and continuing to conduct clinical trials where possible,while navigating the challenges of a worldwide pandemic.We did not lose sight of the patients still waiting for answers,as we added new potential medicines to our portfolio and drove scientific discoveries to fuel the renewal o

5、f our portfolio well into the future.And we did all of this while building our new company and shaping a new culture based on our shared values and focus on patients.After an unprecedented year of progress amid challenges,we have built the company we set out to create.And yet there is more to do for

6、 patients who are waiting.The first year of our new company was truly a remarkable time in BMS history.I am proud of the significant accomplishments we made in the face of great adversity and change during the COVID-19 pandemic.We created a leading biopharma company,a diversified company with leadin